We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Jose A Garcia-Saenz
Mar 18, 2022
Consider a Clinical Trial otherwise Alpelisib, either with FUL or NSAI as ET backbone
THIRU PRASANNA
Mar 18, 2022
Paclitaxel
Sandro Barni
Mar 18, 2022
Continue Fulvestrant and change Abemaciclib to Alpelisib
satadru ray
Mar 18, 2022
Fulvestrant with alpelisib
nadire kucukoztas
Mar 18, 2022
Since the patient is hormone resistant, I recommend capecitabine treatment to the patient.
luis betancourt
Mar 18, 2022
test BRCA
Feng-Jen Chen
Mar 18, 2022
Continue Fulvestrant and change Abemaciclib to Alpelisib
mindy bohrer
Mar 18, 2022
fulvestrant plus alpelisib
hamid rezvani
Mar 18, 2022
continue fulvestrant and replace abemaciclib for alpelisib
pramod kumar julka
Mar 19, 2022
Alpelisib with fulvestrant
Claus Schlotter Prof.Dr.med.
Mar 19, 2022
nab-Paclitaxel weekly
Luca Licata
Mar 19, 2022
The patient had a disease progression 6 months after starting the 1st line endocrine-based therapy (i.e. primary endocrine resistance) and her best response to the 2nd line endocrine-based therapy was a stable disease. I’m not sure that another endocrine-based therapy might be her best option. I would opt for paclitaxel (an oral therapy like capecitabine it’s not the best option in the case of peritoneal metastases and the possible risk of bowel obstruction)
Bogdan Cristian Dinu
Mar 21, 2022
biopsy if it is not so harmfull from peritoneum end adapt treatment afterthat , usually the bone mets are different biology from visceral secondary lesions.
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Ana
C.
Sandoval Leon
MD
Jose A Garcia-Saenz
Mar 18, 2022
THIRU PRASANNA
Mar 18, 2022
Sandro Barni
Mar 18, 2022
satadru ray
Mar 18, 2022
nadire kucukoztas
Mar 18, 2022
luis betancourt
Mar 18, 2022
Feng-Jen Chen
Mar 18, 2022
mindy bohrer
Mar 18, 2022
hamid rezvani
Mar 18, 2022
pramod kumar julka
Mar 19, 2022
Claus Schlotter Prof.Dr.med.
Mar 19, 2022
Luca Licata
Mar 19, 2022
Bogdan Cristian Dinu
Mar 21, 2022
Apr 19, 2024
Pending Moderator approval.